-
Europe's Innovative Medicines Initiative has recruited 7 pharmas to each contribute up to 50,000 compounds from their proprietary libraries for a public-private partnership called the European Lead Factory. The pharmas …
Published on 3/29/2012
-
Instead of taking discoveries from universities and forming companies, BioPontis starts with its knowledge of industry's portfolio needs and works backward. Its alliance so far includes Merck, Pfizer, Janssen Biotech …
Published on 8/4/2011
-
Sage Bionetworks and the Structural Genomics Consortium are spearheading an effort to build a pharma-backed public-private partnership to clinically validate new targets in an IP-free, precompetitive environment. The …
Published on 5/19/2011
-
Agilent is using academic partnerships to get in on the ground floor of synthetic biology, an area the company deems strategically important because it encompasses all three of Agilent's core business areas: electronic …
Published on 5/12/2011
-
Attracted by INSERM's large network of labs and hospitals, MedImmune has formed a strategic collaboration with the institute to explore translational biology and new disease mechanisms and streamline the flow of drug …
Published on 4/28/2011
-
After cutting its teeth with investments in energy and communications, the European Institute for Innovation and Technology is moving into the biopharmaceutical space with plans for a round of seed-stage financing.
Published on 3/10/2011
-
After more than two decades of investing in life science infrastructure, Singapore is shifting its focus and allotting $2.8 billion over the next 5 years to translational research with near-term commercial applications …
Published on 10/28/2010
-
Three recent collaborations are seeking to develop type 1 diabetes therapies that induce insulin-producing cells to regenerate. The compounds could eventually bypass the need for cell therapy, but they still require …
Published on 4/29/2010
-
Lilly, Merck and Pfizer have joined in a precompetitive deal to study the pharmacogenomics of Asian cancer patients. They expect to triple the power of the resulting open-source database at a third of the cost to each …
Published on 3/11/2010
-
CIRM's Expanding Reach Table 1. CIRM grants. Below is a list of 14 research grants awarded by the California Institute for Regenerative Medicine (CIRM) to develop stem cell-based therapies. Lead institution Lead …
Published on 11/12/2009
-
The California Institute for Regenerative Medicine is moving beyond early translation, with its latest grants aiming to produce IND submissions. The awards also begin to reflect CIRM's collaboration with agencies …
Published on 11/12/2009
-
Public-Private Interface: CIRM's clinical mindset Table 1. CIRM-funded translational research. Institution Grant ($M) Indication Stem cell therapies Burnham Institute for Medical Research $3.5 Parkinson's …
Published on 5/7/2009
-
The California Institute for Regenerative Medicine has issued $68 million in grants specifically aimed at moving stem cell research closer to the clinic. The initial winners are institutes and companies focused on …
Published on 5/7/2009
-
Europe's Innovative Medicines Initiative officially unveiled the first 18 projects it will fund under a 5-year, 2 billion program to relieve bottlenecks in drug discovery and development, and for the first time it …
Published on 5/8/2008
-
Public Private Interface: Follow-up: IMI Unveils First Call Table 1. Innovative Medicines Initiative projects. The first call for 18 projects as part of the Innovative Medicines Initiative (IMI) was recently released…
Published on 5/8/2008
-
The European Commission is readying the first call for projects under its Innovative Medicines Initiative with the European Federation of Pharmaceutical Industries and Associations, which will invest some EUR 205 …
Published on 3/27/2008
-
Public Private Interface: Europe's Biomarker Push Table 1. Innovative Medicines Initiative principles on IP. European Federation of Pharmaceutical Industries and Associations members and the European Commission …
Published on 3/27/2008